[ad_1]
Includes oral presentation on Prospera test’s two-threshold algorithm, showing the combination of donor quantity and donor fraction outperforms donor fraction alone
AUSTIN, Texas, June 8, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has presented data on the clinical utility of the company’s Prospera™ and Renasight™ tests in 14 sessions at the American Transplant Congress (ATC) 2022 meeting. This expands on the thirteen peer-reviewed papers that have been published over the last twelve months, demonstrating the strong performance of both assays.
Phil HalloranMD, Ph.D., director of the Alberta Transplant Applied Genomics Centre, presented new data on the latest findings of the global, multisite, prospective Trifecta study, “Combining fraction and estimated amount of dd-cfDNA to assess kidney transplant rejection using molecular diagnoses and histology.” The study demonstrates that the new two-threshold algorithm for the Prospera test – including both dd-cfDNA fraction and quantity – performed better than dd-cfDNA percentage alone in detecting active rejection, with an AUC of 0.88 when compared against molecular biopsy assessment and 0.82 when compared against histological biopsy assessment. This analysis in the Trifecta study features 367 …
Full story available on Benzinga.com
[ad_2]
Source link
